Idéal Investisseur Galteron Galteron
Français English
CAC 40 : Market open
8 317,61 pts
-0.41%


Last updated : 17/11/2026 - 09h25
🏠 Home   ➤    Stock news

Amoéba extends its agreement with Koppert to arboriculture in 19 EU countries

Amoéba's biofungicide, already distributed by Koppert for vines and vegetable crops, is to be extended to a third market: arboriculture, in 19 European Union countries.

According to the press release published on 16 November 2026, this segment represents 10% of the value of the European fungicide market. It ranks fourth, behind wheat, vines and potatoes.


Amoéba extends its agreement with Koppert to arboriculture in 19 EU countries

A third component after vines and vegetables, extended until 2031

Amoéba and the Dutch company Koppert have announced the extension of their distribution agreement to arboriculture. This decision follows an initial phase of co-development and preliminary trials. It comes after the extension, announced on 23 July 2026, of the initial agreement covering vines and vegetable crops until June 2031.

The new agreement targets apples, pears, apricots, quinces, nashi pears, crab apples and medlars. The geographic scope notably covers France, Germany, Italy, Spain, the Netherlands and Poland.

It builds on the recent commercial launch of the Tiagan products for vines and Yazu for vegetable crops, both developed using Amoéba's Axpera technology.

Over 90% efficacy in combined trials, new campaign in 2027

The first joint trial campaign was carried out in 2026 on apple trees in 5 European countries. It focused on apple scab and powdery mildew, the two major diseases of the apple tree. Conducted in combination with conventional fungicides, these trials demonstrated an efficacy of over 90% against these two diseases.

A new trial campaign is planned for 2027 on apples and pears, in order to confirm the performance measured and to test new programmes with arboriculturists. Commercialisation of the product is planned for 2029, subject to obtaining the usual regulatory approvals.

Martin Koppert, product director at Koppert, stated that his group will continue evaluating Axpera “under real growing conditions.” Jean-Marc Petat, managing director of Green for Agro, a subsidiary of Amoéba dedicated to biosolutions, stated: “we will continue the trials with arboriculturists.”

Nearly 600,000 hectares of orchards and a target of 40% of the area

The agreement covers nearly 600,000 hectares of orchards, including 320,000 hectares of apple trees and 80,000 hectares of pear trees. According to the press release, producers generally spend between €1,000 and €1,500 per hectare per year on protecting their crops against fungal diseases.

The two partners aim to eventually protect approximately 40% of the area. Amoéba indicates that this agreement reinforces its target of €40 million in revenue by 2030.

On the financial side, the company announced on 27 October 2026 the successful completion of a €9.7 million capital increase, with settlement and delivery scheduled for 29 October. It then estimated that its financing was secured until September 2027, that is, before the commercialisation date targeted for arboriculture.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Chimie › Biotech industrielle (enzymes, fermentation, biorecyclage, biosourcés)


Context

Period
  • Period: S1 2026
Key reported figures
  • Revenue: 0,1 millions d'euros
  • Quarterly revenue: 0,1 millions d'euros
  • Net income: -7,4 millions d'euros
Guidance from the release
  • La Société pourrait être à la recherche de sources de trésorerie, capitaux et/ou dettes supplémentaires, nécessaires pour assurer le financement de ses activités au-delà du 30 septembre 2027.
Risks mentioned
  • Autorisation définitive d'AXPERA obtenue tardivement (fin juin 2026) après période d'utilisation des produits, affectant les ventes du semestre
  • Monétisation de la plateforme cosmétique dont ni la réalisation, ni le calendrier, ni le montant ne sont acquis à ce jour
  • Besoin de levée de fonds supplémentaire pour assurer continuité d'exploitation jusqu'au 30 septembre 2027 et financer plan de développement
Opportunities identified
  • Autorisation pérenne AXPERA obtenue en France en juin 2026 ouvre la voie à la commercialisation en plusieurs pays européens
  • Accord majeur signé avec Syngenta pour distribution exclusive de la solution en céréales dans 27 pays UE, premiers lancements commerciaux attendus Q3 2028
  • Extension de l'accord de distribution Koppert jusqu'en juin 2031 et potentiel de monétisation de la plateforme cosmétique Willa™ dès 2027
Outlook / guidance
  • Expected revenue: 1,5 millions d'euros
  • Management commentary: Fort des aboutissements des différentes initiatives stratégiques engagées depuis 2023, Amoéba pourra s'appuyer dès 2027 sur la montée en puissance des contrats signés dans le secteur agricole pour atteindre un chiffre d'affaires compris entre 1 et 2 M€.

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours